Drugs News and Research

RSS

Researchers have identified the cellular receptor for the JC virus

Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).

17 Jan 2005

Scientists are a step closer to developing drug targets to treat fungal meningitis

Scientists are a step closer to developing drug targets to treat fungal meningitis -- the infection linked to at least three deaths on Vancouver Island -- thanks to the sequencing of two Cryptococcus genomes by an international team that included researchers at the University of British Columbia and the BC Cancer Agency's Michael Smith Genome Sciences Centre in Vancouver.

17 Jan 2005

Committees will weigh up COX-2 benefits and risks

The U.S. Food and Drug Administration (FDA) has announced a joint public meeting of the agency's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee to be held February 16, 17 and 18, 2005.

16 Jan 2005

How do you remember your own name?

How do you remember your own name? Is it possible ever to forget it? The memory trace, or engram, "feels" like it is stored permanently in the brain and it will never be forgotten.

16 Jan 2005

Discovery offers promise for treatment of age-related hearing loss

Researchers have discovered that deletion of a specific gene permits the proliferation of new hair cells in the cochlea of the inner ear -- a finding that offers promise for treatment of age-related hearing loss. This type of hearing loss is caused by aging, disease, certain drugs, and the cacophony of modern life. It is the most common cause of hearing loss in older people.

13 Jan 2005

Researchers shed new light on the development of cancers, particularly breast and prostate cancer

Researchers at Brown Medical School and Rhode Island Hospital have shed new light on the activation of a protein key to the development of cancers, particularly breast and prostate cancer, the most commonly diagnosed cancers in the United States.

13 Jan 2005

New figures highlight trends in drug and alcohol misuse

New figures published by Dr Foster* in this week's BMJ outline drug and alcohol related harm in the population of England.

13 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Alternative therapies and conventional medical therapies should be held to same standards

Stating that health care should strive to be both comprehensive and evidence-based, a new report from the Institute of Medicine of the National Academies calls for conventional medical treatments and complementary and alternative treatments to be held to the same standards for demonstrating clinical effectiveness.

13 Jan 2005

Study identifies potentially valuable applications for new drug Nifrolidine

Along with aiding efforts to study addicted smokers, a new drug that attaches only to areas of the brain that have been implicated in nicotine addiction may help studies of people battling other disorders such as Alzheimer’s disease and schizophrenia.

12 Jan 2005

Steady points to need for more rigorous evaluation of complementary & alternative medicine use

In a comparison of complementary and alternative medicine (CAM) use by adults in 1997 and 2002, researchers from Harvard Medical School found more than one in three U.S. adults (36.5 and 35.0 percent, respectively) used at least one form of CAM.

12 Jan 2005

Scientists uncover new evidence to help explain statins’ effects in Alzheimer’s disease

Scientists at Jefferson Medical College and the Farber Institute for Neurosciences at Thomas Jefferson University in Philadelphia have taken another step in understanding the potential effects of anti-cholesterol drugs on Alzheimer’s disease.

12 Jan 2005

Euro funding for diabetes and exercise research

Researchers at The University of Nottingham are among a network of European scientists who have been awarded €12.7 million (around £8.7 million) for a study into the relationship between lack of exercise and the development of diabetes — and the health benefits of regular exercise in its prevention and cure.

12 Jan 2005

Survey finds online health information poised to become important resource for seniors, but not there yet

As the Internet becomes an increasingly important resource for informing decisions about health and health care options, a new national survey of older Americans by the Kaiser Family Foundation finds that less than a third (31%) of seniors (age 65 and older) have ever gone online, but that more than two-thirds (70%) of the next generation of seniors (50-64 year-olds) have done so.

12 Jan 2005

Lowering health care costs overall seen as top U.S. health priority

The public favors reducing jury awards in malpractice lawsuits and allowing drugs to be imported from Canada, but ranks them relatively low on a list of 12 health care priorities for President Bush and Congress to address this year, according to a new post-election survey conducted by the Kaiser Family Foundation and the Harvard School of Public Health.

12 Jan 2005

First deceleration in U.S. national health spending growth in seven years

The pace of health spending growth slowed in 2003, marking the first deceleration in national health spending growth in seven years, a report by the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary shows. The annual report is published in the January/February 2005 issue of Health Affairs.

12 Jan 2005

Research breakthrough in treatment of TB and MDR-TB

FASgen Inc.'s compound, FAS20013, has emerged from an intense multi-year program of pre-clinical studies that clearly validate its potential as an ideal new drug for the treatment of tuberculosis and MDR-TB, the disease caused by organisms that are resistant to the drugs now commonly used to treat TB. Initial clinical trials in both TB and MDR-TB are scheduled for later this year.

12 Jan 2005

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Myriad Genetics announced today that it has initiated enrollment in a Phase 3 human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

12 Jan 2005

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

Important clue to understanding the origins of the AIDS epidemic

Medical Research Council (MRC) scientists have uncovered an important clue to understanding the origins of the AIDS epidemic. The work suggests that harnessing natural mechanisms of resistance to HIV infection might provide new methods for combating AIDS.

12 Jan 2005